Prognostic significance of nuclear factor-kappaB p105/p50 in human melanoma and its role in cell migration.
暂无分享,去创建一个
M. Martinka | Gang Li | K. Gao | D. Dai
[1] F. Haluska,et al. Genetic Alterations in Signaling Pathways in Melanoma , 2006, Clinical Cancer Research.
[2] D. Toomre,et al. Lymphocyte transcellular migration occurs through recruitment of endothelial ICAM-1 to caveola- and F-actin-rich domains , 2006, Nature Cell Biology.
[3] H. Stein,et al. Elevated NF-κB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas , 2005 .
[4] Alan Hall,et al. Rho GTPases: biochemistry and biology. , 2005, Annual review of cell and developmental biology.
[5] M. Falasca,et al. Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration , 2005, The Journal of cell biology.
[6] A. Richmond,et al. Role of nuclear factor-κ B in melanoma , 2005, Cancer and Metastasis Reviews.
[7] Gioacchino Natoli,et al. Interactions of NF-κB with chromatin: the art of being at the right place at the right time , 2005, Nature Immunology.
[8] S. Husain,et al. Constitutive activation of nuclear factor -kB: preferntial homodimerization of p50 subunits in cervical carcinoma. , 2005, Frontiers in bioscience : a journal and virtual library.
[9] R. Ricciardi,et al. DNA Binding of Repressor Nuclear Factor-κB p50/p50 Depends on Phosphorylation of Ser337 by the Protein Kinase A Catalytic Subunit* , 2005, Journal of Biological Chemistry.
[10] M. Martinka,et al. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] P. Gassmann,et al. Role of Tumor Cell Adhesion and Migration in Organ-Specific Metastasis Formation , 2004, Oncology Research and Treatment.
[12] A. Ridley,et al. Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. , 2004, Experimental cell research.
[13] Ann Richmond,et al. Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition , 2004, Cancer Research.
[14] F. Meyskens,et al. Comparative expression of NFkappaB proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies. , 2004, Pigment cell research.
[15] M. Javadi,et al. NF-kappaB binds to a polymorphic repressor element in the MMP-3 promoter. , 2004, Biochemical and biophysical research communications.
[16] Krister Wennerberg,et al. Rho and Rac Take Center Stage , 2004, Cell.
[17] G. Borisy,et al. Cell Migration: Integrating Signals from Front to Back , 2003, Science.
[18] R. Pathmanathan,et al. Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. , 2003, Cancer research.
[19] Z. Ronai,et al. Death receptors and melanoma resistance to apoptosis , 2003, Oncogene.
[20] M. Hendrix,et al. Molecular plasticity of human melanoma cells , 2003, Oncogene.
[21] S. Lowe,et al. Apoptosis and melanoma chemoresistance , 2003, Oncogene.
[22] R. K Srivastava,et al. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. , 2003, Cancer research.
[23] Jennifer Y. Zhang,et al. NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia , 2003, Nature.
[24] P. Hersey,et al. Adjuvant therapy for high‐risk primary and resected metastatic melanoma , 2003, Internal medicine journal.
[25] A. Hall,et al. Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. , 2002, Genes & development.
[26] Michael Karin,et al. NF-κB at the crossroads of life and death , 2002, Nature Immunology.
[27] D. Granger,et al. Endothelial Expression of Vascular Cell Adhesion Molecule‐1 Correlates with Metastatic Pattern in Spontaneous Melanoma , 2001, Microcirculation.
[28] Martin F. Mihm,et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] L. Ziegler-Heitbrock. The p50-homodimer mechanism in tolerance to LPS , 2001, Journal of endotoxin research.
[30] R. Marks,et al. Epidemiology of melanoma , 2000, Clinical and experimental dermatology.
[31] G. Salvesen,et al. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas , 2000, Current Biology.
[32] M. Boyano,et al. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients withelanoma , 2000, British Journal of Cancer.
[33] Eric S. Lander,et al. Genomic analysis of metastasis reveals an essential role for RhoC , 2000, Nature.
[34] A. Marghoob,et al. Breslow thickness and Clark level in melanoma , 2000, Cancer.
[35] S. Narumiya,et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. , 1999, Science.
[36] W. Kiosses,et al. Regulation of the small GTP‐binding protein Rho by cell adhesion and the cytoskeleton , 1999, The EMBO journal.
[37] A. Hall,et al. Rho GTPases and the actin cytoskeleton. , 1998, Science.
[38] A. Richmond,et al. Enhanced Degradation of I-κBα Contributes to Endogenous Activation of NF-κB in Hs294T Melanoma Cells , 1997 .
[39] R. Bravo,et al. Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. , 1997, Genes & development.
[40] David Baltimore,et al. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB , 1995, Nature.
[41] G. Rosen,et al. Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1). , 1992, The Journal of biological chemistry.
[42] A. Jemal,et al. Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.
[43] M. Piris,et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. , 2004, The American journal of pathology.
[44] D. Altieri,et al. Drug Resistance in Melanoma: Mechanisms, Apoptosis, and New Potential Therapeutic Targets , 2004, Cancer and Metastasis Reviews.
[45] R. Wadhwa,et al. Cell migration and metastasis as targets of small RNA-based molecular genetic analyses , 2004, Journal of Muscle Research & Cell Motility.
[46] M. Ballo,et al. Radiation therapy for malignant melanoma. , 2003, The Surgical clinics of North America.
[47] Ahmedin Jemal,et al. Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.
[48] G. Riethmüller,et al. De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. , 1989, Proceedings of the National Academy of Sciences of the United States of America.